Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc (FRLN) Revenue
Annual & quarterly revenue history · segment & region breakdown
FRLN · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsFreeline Therapeutics Holdings plc trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2022.
Revenue trend
2022 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Freeline Therapeutics Holdings plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Freeline Therapeutics Holdings plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Freeline Therapeutics Holdings plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
FRLN revenue · 4 questionsFRLN's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2022.
▸ Source: FMP · Freeline Therapeutics Holdings plc SEC filings · GAAP · Freeline Therapeutics Holdings plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026